W2O – a leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector – announced the acquisition of Symplur, a social media analytics platform exclusively focused on the healthcare sector.
The U.S. Food and Drug Administration granted emergency use authorization (EUA) to Rutgers’ RUCDR Infinite Biologics for a test that uses saliva.
While the world waits for a vaccine against SARS-CoV-2 – the novel coronavirus that causes COVID-19 – one likely control and exit strategy is testing for immunity, or an antibody test.
Gilead Sciences is running at least five clinical trials for the company’s experimental antiviral drug remdesivir against COVID-19.
The American Medical Association (AMA) doubled down on the organization’s stance against using off-label medicines such as hydroxychloroquine and chloroquine to treat COVID-19 patients.
China’s CanSino Biologics is advancing a COVID-19 vaccine candidate into Phase II, putting the company ahead of others in the race against the novel coronavirus.
Signals Analytics’ online COVID-19 Playbook is an analytics platform that uses external data that uncover trends and predictive insights.
A new weapon in the war on coronavirus is on the way. Leading health creative agency The Bloc developed SafeCode, a unique device concept which fuses a barcode scanner with UV-C light technology proven to destroy dangerous viruses and bacteria, and is expected to do the same to SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19).
Novartis and Incyte are launching a Phase III clinical trial to determine if the cancer drug Jakavi (ruxolitinib) can be used to treat COVID-19.
With all the similarities, there are several significant differences between the COVID-19 and the Spanish Flu of 1918 pandemics.
